These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19341847)

  • 1. Side effects from the copper IUD: do they decrease over time?
    Hubacher D; Chen PL; Park S
    Contraception; 2009 May; 79(5):356-62. PubMed ID: 19341847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can intrauterine device removals for bleeding or pain be predicted at a one-month follow-up visit? A multivariate analysis.
    Stanback J; Grimes D
    Contraception; 1998 Dec; 58(6):357-60. PubMed ID: 10095972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adolescent Experiences With Intrauterine Devices: A Qualitative Study.
    Schmidt EO; James A; Curran KM; Peipert JF; Madden T
    J Adolesc Health; 2015 Oct; 57(4):381-6. PubMed ID: 26126950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
    Suvisaari J; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.
    Chen JH; Wu SC; Shao WQ; Zou MH; Hu J; Cong L; Miao L; Wang C; Dong J; Gao J; Xiao BL
    Contraception; 1998 Jun; 57(6):371-9. PubMed ID: 9693396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performances of copper T 380A and multiload copper 375/250 intrauterine contraceptive devices in a comparative clinical trial.
    Arowojolu AO; Otolorin EO; Ladipo OA
    Afr J Med Med Sci; 1995 Mar; 24(1):59-65. PubMed ID: 7495202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menstrual problems and side effects associated with long-term TCu 380A IUD use in perimenopausal women.
    Reinprayoon D; Taneepanichskul S
    Contraception; 1998 Jun; 57(6):417-9. PubMed ID: 9693403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary report on a postpartum CuT 200 study, Santiago, Chile.
    Lavin P; Waszak C; Bravo C
    Int J Gynaecol Obstet; 1983 Feb; 21(1):71-5. PubMed ID: 6133798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen.
    Hubacher D; Reyes V; Lillo S; Pierre-Louis B; Zepeda A; Chen PL; Croxatto H
    Hum Reprod; 2006 Jun; 21(6):1467-72. PubMed ID: 16484309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of copper surface area on menstrual blood loss and iron status in women fitted with an IUD.
    Milsom I; Rybo G; Lindstedt G
    Contraception; 1990 Mar; 41(3):271-81. PubMed ID: 2323218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can intrauterine contraceptive devices lead to VulvoVaginal Candidiasis (VVC) and Anemia in Iranian new users?
    Behboudi-Gandevani S; Imani S; Moghaddam-Banaem L; Roudbar-Mohammadi S
    Sex Reprod Healthc; 2015 Mar; 6(1):40-3. PubMed ID: 25637424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The acceptability of current contraceptive methods to adolescents].
    Sotnikova EI; Dubnitskaia LV; Perminova SG
    Akush Ginekol (Mosk); 1993; (3):26-30. PubMed ID: 8048682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR).
    Sivin I; Stern J
    Fertil Steril; 1994 Jan; 61(1):70-7. PubMed ID: 8293847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance of the TCu 380A and Lippes Loop IUDs in three developing countries.
    Farr G; Amatya R; Acosta M; Ekwempu C; Kisninci H
    Contraception; 1995 Jul; 52(1):17-22. PubMed ID: 8521710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-month comparative multicenter study of the TCu 380A and ML 250 intrauterine devices in Bangkok, Thailand.
    Reinprayoon D; Gilmore C; Farr G; Amatya R
    Contraception; 1998 Oct; 58(4):201-6. PubMed ID: 9865999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year clinical experience with FlexiGard.
    Batar I
    Contraception; 1992 Oct; 46(4):307-12. PubMed ID: 1486769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study.
    Peebles K; Kiweewa FM; Palanee-Phillips T; Chappell C; Singh D; Bunge KE; Naidoo L; Makanani B; Jeenarain N; Reynolds D; Hillier SL; Brown ER; Baeten JM; Balkus JE;
    Clin Infect Dis; 2021 Aug; 73(3):513-520. PubMed ID: 32505132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.